Bayesian phase II clinical trial design with noncompliance
From MaRDI portal
Publication:6628481
DOI10.1002/SIM.9041zbMATH Open1546.6262MaRDI QIDQ6628481FDOQ6628481
Authors: Tingyang Ren, Weining Shen, Liwen Zhang, Hai Bing Zhao 
Publication date: 29 October 2024
Published in: Statistics in Medicine (Search for Journal in Brave)
variable selectionnoncomplianceprincipal stratificationBayesian designBayesian additive regression treecomplier average causal effect
Cites Work
- Variable selection for BART: an application to gene regulation
- BART: Bayesian additive regression trees
- Principal stratification in causal inference
- Bayesian Analysis of Binary and Polychotomous Response Data
- Assessing the effect of an influenza vaccine in an encouragement design
- Bayesian inference for causal effects in randomized experiments with noncompliance
- Causal inference in statistics: an overview
- Addressing complications of intention-to-treat analysis in the combined presence of all-or-none treatment-noncompliance and subsequent missing outcomes
- One-Sample Multiple Testing Procedure for Phase II Clinical Trials
- Principal stratification with predictors of compliance for randomized trials with 2 active treatments
- The potential for bias in principal causal effect estimation when treatment received depends on a key covariate
- Stochastic counterfactuals and stochastic sufficient causes
- Practical Bayesian Guidelines for Phase IIB Clinical Trials
- Adaptive Two-Stage Designs for Single-Arm Phase IIA Cancer Clinical Trials
- A Bayesian phase I/II clinical trial design in the presence of informative dropouts
- Bayesian inference for a principal stratum estimand to assess the treatment effect in a subgroup characterized by postrandomization event occurrence
This page was built for publication: Bayesian phase II clinical trial design with noncompliance
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q6628481)
